0.289

0.34% 0.0028

Cara Therapeutics Inc (CARA)

Overview News Price History Option Chain Financials Why CARA Down? Discussions Forecast Stock Split

Cara Therapeutics Inc stock is traded at $0.289, with a volume of 164.69K. It is up +0.34% in the last 24 hours and up +6.24% over the past month. Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Previous Close:

$0.2918

Open:

$0.29

24h Volume:

164.69K

Relative Volume:

0.48

Market Cap:

$16.09M

Revenue:

$20.97M

Net Income/Loss:

$-118.51M

P/E Ratio:

-0.1403

EPS:

-2.06

Net Cash Flow:

$-94.45M

1W Performance:

+9.70%

1M Performance:

+6.24%

6M Performance:

-62.37%

1Y Performance:

-78.31%

1-Day Range:

$0.281

$0.298

1-Week Range:

$0.26

$0.3199

52-Week Range:

$0.24

$1.40

Cara Therapeutics Inc Stock (CARA) Company Profile

Name

Cara Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

203-406-3700

Address

400 ATLANTIC STREET, SUITE 500, STAMFORD, CT

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CARA's Discussions on Twitter

Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-08-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-08-22	Upgrade	JP Morgan	Neutral → Overweight
Nov-01-21	Resumed	Canaccord Genuity	Buy
Aug-03-21	Initiated	JP Morgan	Neutral
Apr-21-20	Reiterated	H.C. Wainwright	Buy
Aug-12-19	Reiterated	H.C. Wainwright	Buy
May-29-19	Reiterated	Laidlaw	Buy
Feb-06-19	Resumed	Jefferies	Buy
Jan-15-19	Initiated	BofA/Merrill	Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Jefferies	Buy
Aug-08-18	Reiterated	Stifel	Buy
Jun-28-18	Reiterated	H.C. Wainwright	Buy
Mar-12-18	Resumed	H.C. Wainwright	Buy
Feb-12-18	Upgrade	Janney	Neutral → Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jun-30-17	Downgrade	Janney	Buy → Neutral
Jun-30-17	Reiterated	Laidlaw	Buy
Jun-30-17	Reiterated	Stifel	Buy
Mar-28-17	Reiterated	H.C. Wainwright	Buy
Mar-28-17	Reiterated	Laidlaw	Buy
Mar-10-17	Reiterated	Laidlaw	Buy
Oct-13-16	Initiated	H.C. Wainwright	Buy
Aug-08-16	Reiterated	Needham	Buy

View All

Cara Therapeutics Inc Stock (CARA) Latest News

01:41 AM

Cara Operations (TSE:CARA) Stock Price Down 2.4% – Here’s Why - Defense World

01:41 AM

Nov 01, 2024

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues - Simply Wall St

Nov 01, 2024

Oct 31, 2024

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update - Quantisnow

Oct 31, 2024

Riskified Ltd. (NYSE:RSKD) Given Consensus Recommendation of “Hold” by Analysts - Defense World

Oct 16, 2024

Oct 13, 2024

Heritage Global Inc. (NASDAQ:HGBL) Shares Acquired by Dimensional Fund Advisors LP - Defense World

Oct 13, 2024

Dimensional Fund Advisors LP Purchases 55,636 Shares of VirTra, Inc. (NASDAQ:VTSI) - Defense World

Oct 13, 2024

Renaissance Technologies LLC Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World

Oct 13, 2024

Oct 10, 2024

Opioid Use Disorder (OUD) Market Report 2024: Growth, Trends, Competitive Outlook to 2033 - WhaTech

Oct 10, 2024

Oct 09, 2024

Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024

Oct 07, 2024

Financial Health Report: Cara Therapeutics Inc (CARA)’s Ratios Tell a Tale - The Dwinnex

Oct 07, 2024

What technical indicators reveal about CARA stock - US Post News

Oct 07, 2024

Oct 04, 2024

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Quantisnow

Oct 04, 2024

Medical Marijuana Market Report 2024Growth, Forecast In The Latest Research - WhaTech

Oct 04, 2024

Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World

Oct 04, 2024

Sep 30, 2024

Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex

Sep 30, 2024

Sep 29, 2024

Cara Therapeutics, Inc. (NASDAQ:CARA) Sees Large Increase in Short Interest - Defense World

Sep 29, 2024

Sep 26, 2024

Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World

Sep 26, 2024

Sep 25, 2024

G-Protein Coupled Receptors Market Growth Analysis, Trends, Share, Market Size And Forecast To 2033 - WhaTech

Sep 25, 2024

Sep 23, 2024

A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News

Sep 23, 2024

Sep 21, 2024

WesBanco, Inc. (NASDAQ:WSBC) Receives Consensus Rating of “Hold” from Analysts - Defense World

Sep 21, 2024

Sep 19, 2024

Pruritus Clinical Trials 2024: FDA Approvals, Medication, - openPR

Sep 19, 2024

Sep 18, 2024

Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada

Sep 18, 2024

Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com

Sep 18, 2024

Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Sep 18, 2024

Carmat launches capital increase, stock plummets - Marketscreener.com

Sep 18, 2024

Sep 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire

Sep 17, 2024

Most Promising New Drugs for Hidradenitis Suppurativa, with Raj Chovatiya, MD, PhD - MD Magazine

Sep 17, 2024

Sep 16, 2024

The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News

Sep 16, 2024